50
Participants
Start Date
April 4, 2025
Primary Completion Date
November 30, 2026
Study Completion Date
November 15, 2027
Satralizumab
Satralizumab will be administered SC in the abdominal or femoral region on Day 1, Weeks 2 and 4 (loading doses) and then Q4W from Weeks 8 to 104 (maintenance doses) until the study completion visit.
RECRUITING
Columbia University Medical Center, New York
RECRUITING
IRCCS Istituto G. Gaslini, Genoa
RECRUITING
Fondazione IRCCS Istituto Neurologico ?Carlo Besta?, Milan
RECRUITING
Child's Hosp King's Daughters, Norfolk
RECRUITING
Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta
RECRUITING
Hospital U. Central de Asturias, Asturias
RECRUITING
Hospital Universitario la Fe, Valencia
RECRUITING
Corewell Health, Grand Rapids
RECRUITING
Arkansas Children's Hospital, Little Rock
RECRUITING
Neurology Rare Disease Center, Denton
RECRUITING
University of Massachusetts Memorial Childrens Medical Center, Worcester
RECRUITING
Policlinico Agostino Gemelli, Rome
RECRUITING
Instytut Centrum Zdrowia Matki Polki, ?ód?
RECRUITING
Uniwersyteckie Centrum Kliniczne, Gda?sk
RECRUITING
Uniwersytecki Szpital Kliniczny w Poznaniu, Późna
RECRUITING
Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny, Warsaw
RECRUITING
Hospital Sant Joan De Deu, Esplugues de Llobregas
RECRUITING
Hospital Universitario Torrecardenas;Servicio de Neurologia, Almería
Hoffmann-La Roche
INDUSTRY